Sort
10,766 grants matching “checkpoint inhibitor”
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
$621,608Ticiana Leal · Emory University · UG1 · FY2023 · CA
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer
$621,551Nirav Thosani · University Of Texas Hlth Sci Ctr Houston · R01 · FY2024 · CA
Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer
$621,239Ming You · Medical College Of Wisconsin · R01 · FY2019 · CA
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
$621,000Stuart J Kahn · Syntrix Biosystems, Inc. · R44 · FY2017 · CA
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
$620,991Lauren Averett Byers · University Of Tx Md Anderson Can Ctr · U01 · FY2021 · CA
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer
$620,943Rebecca L Aft · Washington University · R01 · FY2024 · CA
Functions of mutant IDH in cholangiocarcinoma
$620,855Nabeel Bardeesy · Massachusetts General Hospital · R01 · FY2024 · CA
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
$620,831Edward B Garon · University Of California Los Angeles · R01 · FY2023 · CA
Investigating CREB5-driven mechanisms of immune therapy resistance
$620,820Robert Thomas Manguso · Massachusetts General Hospital · R01 · FY2025 · CA
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
$620,740Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2023 · CA
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors
$620,673Miguel Angel Villalona · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA
Identifying senescence and immune biomarkers predictive of benefit to combined CDK4 and checkpoint blockade inhibition in patients with dedifferentiated liposarcoma
$620,672Sandra P D'angelo · Sloan-Kettering Inst Can Research · R01 · FY2024 · FD
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression
$620,565Heide L Ford · University Of Colorado Denver · R01 · FY2021 · CA
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression
$620,565Heide L Ford · University Of Colorado Denver · R01 · FY2020 · CA
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression
$620,565Heide L Ford · University Of Colorado Denver · R01 · FY2018 · CA
Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer
$620,514Harry H Yoon · Mayo Clinic Rochester · R01 · FY2023 · CA
Tunneling Nanotube Inhibitors for Cancer Immunotherapy
$620,466Shiladitya Sengupta · Brigham And Women'S Hospital · R01 · FY2024 · CA
Therapeutic approaches for LKB1-deficient non-small cell lung cancer
$620,252John V. Heymach · University Of Tx Md Anderson Can Ctr · R01 · FY2016 · CA
Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCC
$620,173Satdarshan Singh Monga · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
$620,060Pawel K. Mazur · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Novel Radiomics for Predicting Response to Immunotherapy for Lung Cancer
$619,994Anant Madabhushi · Case Western Reserve University · R01 · FY2021 · CA
Improving the platelet-mediated immune checkpoint inhibitor delivery for treating triple-negative breast cancer
$619,764Quanyin Hu · University Of Wisconsin-Madison · R01 · FY2025 · CA
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
$619,714Jin Wang · Baylor College Of Medicine · R01 · FY2023 · CA
Targeting B7-H3 in ovarian cancer
$619,664Gianpietro Dotti · Univ Of North Carolina Chapel Hill · R01 · FY2022 · CA
Mechanisms of BET bromodomain metabolic reprogramming in triple negative breast cancer
$619,610Gerald V Denis · Boston University Medical Campus · R01 · FY2021 · CA